Advertisement |
 |
| |
|
 |
TABLE OF CONTENTS
|
December 2018 Volume 17, Issue 12 |
 | | |
 |  Comment
News and Analysis
Research Highlights
Reviews
Erratum
Corrigenda
| | | Advertisement | | | | =======================
Register for the latest nature.com webcast
Use of Simoa Planar Protein Multiplex Arrays as a Sensitive Biomarker Platform in Oncology Clinical Trials – Wednesday, December 12, 2018
Register for FREE today
Sponsored by: Quanterix
======================
| | |
| |
Advertisement |
|
Johnson & Johnson Innovation is searching for the best and brightest innovators in healthcare! Apply for the exclusive opportunity to present your game-changing idea to J&J leadership during the week of the 37th Annual JP Morgan Healthcare Conference in San Francisco. Don't delay! Applications close December 7.
Learn more about the Quick Pitch and submit applications here. |  | | |
|
| |
| Advertisement |
|
|
|
| |
Advertisement |
|
Winners announced!
We are delighted to announce the first ever winners of the Nature Research Awards for Inspiring Science and Innovating Science, in partnership with The Estée Lauder Companies. Congratulations to both our Award winners!
See who's won >
In partnership with The Estée Lauder Companies. | | |
|
| |
Comment | |
| |
The evolution of adaptiveness: balancing speed and evidence
Hans-Georg Eichler, Richard Barker, Nicola Bedlington, Jacoline C. Bouvy, André W. Broekmans et al.
pp845 - 846 | doi:10.1038/nrd.2018.90
'Adaptive' approaches to bringing drugs to market have been widely discussed in recent years. Here, we describe the evolution of the adaptive approach and of concepts developed by ADAPT SMART, a multi-stakeholder consortium funded by the European Innovative Medicines Initiative.
Full Text | PDF
|
News and Analysis | |
| |
Phosphatases start shedding their stigma of undruggability
Asher Mullard
pp847 - 849 | doi:10.1038/nrd.2018.201
Clinical-stage allosterically acting drugs are on track to unlock a stubborn class of targets.
Full Text | PDF
Collection: Cancer at Nature Research
|
FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on
Asher Mullard
pp850 - 851 | doi:10.1038/nrd.2018.206
A panel of independent experts voted narrowly in favour of continuing to require cardiovascular outcomes data for new diabetes drugs, but urged relaxation and simplification of the safety assessment.
Full Text | PDF
|
|
| News in Brief |
|
Anti-inflammatory cardiovascular therapies take another hit
Asher Mullard
p853 | doi:10.1038/nrd.2018.218
Full Text | PDF
|
FDA approves first new flu drug in 20 years
Asher Mullard
p853 | doi:10.1038/nrd.2018.219
Full Text | PDF
|
RNAi deal flow heats up
Asher Mullard
p853 | doi:10.1038/nrd.2018.220
Full Text | PDF
|
|
| Biobusiness Briefs |
|
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Jun Tang, Jia Xin Yu, Vanessa M. Hubbard-Lucey, Svetoslav T. Neftelinov, Jeffrey P. Hodge et al.
pp854 - 855 | doi:10.1038/nrd.2018.210
Full Text | PDF
Collection: Cancer at Nature Research
|
Market watch: The industry's biggest drug launches
Lisa Urquhart
p855 | doi:10.1038/nrd.2018.209
Full Text | PDF
Collection: Cancer at Nature Research
|
|
| An Audience With |
|
Samantha Du
pp856 - 857 | doi:10.1038/nrd.2018.208
Samantha Du, CEO of Zai Lab and former CSO of Chi-Med, talks about the burgeoning Chinese biopharma ecosystem.
Full Text | PDF
|
|
| From the analyst's couch |
|
Reforming China's drug regulatory system
Lili Xu, Huijun Gao, Kenneth I. Kaitin & Liming Shao
pp858 - 859 | doi:10.1038/nrd.2018.150
Since 2015, the Chinese government has introduced numerous reforms with the aim of establishing a more scientific and efficient drug regulatory system, which are highlighted here.
Full Text | PDF
|
| Advertisement |
|
Searching for a new career?
At Nature Research we frequently recruit talented individuals to join our editorial and publishing teams. If you have a PhD and a passion for science this may be the perfect career for you.
Visit our research editorial and publishing careers website to discover more about what we do |  | | |
|
| |
Research Highlights | |
| |
| |
| Advertisement |
|
Why is innate immunity an under-appreciated aspect of immunotherapy?
Researchers have now identified methods to elicit the innate immune system to exhibit heightened anti-infective activity while at the same time decreasing the inflammatory response.
Could this offer a new approach for immunotherapy? Read more here >>
In association with Soligenix |  | | |
|
| |
|
 |
Reviews | |
| |
Mitochondria as a therapeutic target for common pathologies
Michael P. Murphy & Richard C. Hartley
pp865 - 886 | doi:10.1038/nrd.2018.174
Mitochondrial dysfunction contributes to many common disorders, and therapeutic strategies aimed at restoring mitochondrial function are now emerging, with a small number of agents now in clinical trials. Here, Murphy and Hartley assess therapeutic approaches and challenges in targeting mitochondria and highlight examples of promising indications.
Full Text | PDF
|
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta & Jeffrey W. Pollard
pp887 - 904 | doi:10.1038/nrd.2018.169
Tumour-associated macrophages (TAMs) promote cancer initiation and malignant progression. This Review evaluates current strategies to target TAMs, exploring their toxicity and compensatory mechanisms, and proposes novel strategies in light of new findings regarding macrophage biology and their mechanism of action.
Full Text | PDF
|
Therapeutic strategies targeting connexins
Dale W. Laird & Paul D. Lampe
pp905 - 921 | doi:10.1038/nrd.2018.138
The connexin family of channel-forming proteins is critical for cellular communication, being involved in both health and disease. Here, Laird and Lampe assess the potential of connexins as therapeutic targets in acquired and inherited diseases, as well as wound repair, highlighting agents currently in development and the associated clinical challenges.
Full Text | PDF
|
Erratum | |
| |
Trends in the global immuno-oncology landscape
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey & Vanessa M. Hubbard-Lucey
p922 | doi:10.1038/nrd.2018.202
Full Text | PDF
|
Corrigenda | |
| |
Expanding the medicinal chemistry synthetic toolbox
Jonas Boström, Dean G. Brown, Robert J. Young & György M. Keserü
p922 | doi:10.1038/nrd.2018.217
Full Text | PDF
|
| Advertisement |
|
===================================
Register for the latest nature.com webcast
Bioengineering Custom Cell Microenvironments with Versatile Maskless Photopatterning
Register for FREE today
Sponsored by: Alvéole
================================== | | |
|
| |
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
|
No comments:
Post a Comment